Industry criticises EPO plansEuropean life sciences industry associations have voiced concerns over the latest addition to the European Patent Offices ambitious Early Certainty Initiative. While cutting the time for determining … more ➔
Microfluidics: Mapping DNA-bindersScientists at EPFL in Lausanne have developed a semi-automated technology that may be a game-changer by making the characterisation of the 2,000 DNA-binding proteins much faster, more accurate, and … more ➔
Next Big Thing in insurance: Digitalising...To date, insurance business models have always been based on damage control, but that paradigm is changing. Some insurers are now trying to hedge bets by motivating customers to get healthier and track … more ➔
Bioprinting: Screening drugs in multiple d...90% of all preclinical drug candidates fail to make the grade. Now novel methods that employ miniaturised organs could help overcome this healthcare hurdle. Researchers and CROs are testing a range of … more ➔
Biopesticides: Of strawberries and antibod...Over the last decade, therapeutic antibodies have fundamentally changed approaches in different areas of medicine, providing the impetus for a big leap forward in the treatment of cancers and autoimmune … more ➔
Real World Data: Beyond clinical trialsOnly a small fraction of carefully selected patients are allowed to enroll in randomised controlled trials involving new compounds – the gold standard of drug assessment. But trying to acquire the most … more ➔
Exosomes: Extracellular and extraordinaryDisregarded for decades, extracellular vesicles are now understood to be a key element in communication between cells. Discoveries around the nano-sized bubbles are revolutionising not only the field … more ➔
Sepsis: Targeting a silent killerFor over three decades, attempts among drug developers to target the inflammatory pathways and symptoms of sepsis have been fruitless. New rapid diagnostics, rigourous patient stratification and drugs … more ➔
The CO2 opportunityAlthough most people still view carbon dioxide (CO2) as a climate killer, industry is beginning to realise that CO2 could actually provide an abundant, low-cost feedstock for carbon-based processes. … more ➔
En route to Adaptive PathwaysThe European Medicines Agencys new, accelerated route to approval for innovative drugs seems to be especially attractive for biotech companies. But Health Technology Assessment institutions warn that … more ➔
